AAPL   312.11 (-2.56%)
FB   210.04 (-2.12%)
MSFT   178.35 (-3.29%)
GOOGL   1,485.52 (-2.07%)
AMZN   2,099.59 (-2.49%)
CGC   21.94 (-1.66%)
NVDA   293.67 (-4.87%)
BABA   212.66 (-2.47%)
MU   56.56 (-4.15%)
GE   12.29 (-1.92%)
TSLA   899.52 (+0.01%)
AMD   53.15 (-7.19%)
T   38.45 (-0.41%)
ACB   1.67 (-0.60%)
F   7.91 (-1.49%)
BAC   34.25 (-1.75%)
DIS   138.70 (-1.19%)
GILD   69.22 (+3.31%)
AAPL   312.11 (-2.56%)
FB   210.04 (-2.12%)
MSFT   178.35 (-3.29%)
GOOGL   1,485.52 (-2.07%)
AMZN   2,099.59 (-2.49%)
CGC   21.94 (-1.66%)
NVDA   293.67 (-4.87%)
BABA   212.66 (-2.47%)
MU   56.56 (-4.15%)
GE   12.29 (-1.92%)
TSLA   899.52 (+0.01%)
AMD   53.15 (-7.19%)
T   38.45 (-0.41%)
ACB   1.67 (-0.60%)
F   7.91 (-1.49%)
BAC   34.25 (-1.75%)
DIS   138.70 (-1.19%)
GILD   69.22 (+3.31%)
AAPL   312.11 (-2.56%)
FB   210.04 (-2.12%)
MSFT   178.35 (-3.29%)
GOOGL   1,485.52 (-2.07%)
AMZN   2,099.59 (-2.49%)
CGC   21.94 (-1.66%)
NVDA   293.67 (-4.87%)
BABA   212.66 (-2.47%)
MU   56.56 (-4.15%)
GE   12.29 (-1.92%)
TSLA   899.52 (+0.01%)
AMD   53.15 (-7.19%)
T   38.45 (-0.41%)
ACB   1.67 (-0.60%)
F   7.91 (-1.49%)
BAC   34.25 (-1.75%)
DIS   138.70 (-1.19%)
GILD   69.22 (+3.31%)
AAPL   312.11 (-2.56%)
FB   210.04 (-2.12%)
MSFT   178.35 (-3.29%)
GOOGL   1,485.52 (-2.07%)
AMZN   2,099.59 (-2.49%)
CGC   21.94 (-1.66%)
NVDA   293.67 (-4.87%)
BABA   212.66 (-2.47%)
MU   56.56 (-4.15%)
GE   12.29 (-1.92%)
TSLA   899.52 (+0.01%)
AMD   53.15 (-7.19%)
T   38.45 (-0.41%)
ACB   1.67 (-0.60%)
F   7.91 (-1.49%)
BAC   34.25 (-1.75%)
DIS   138.70 (-1.19%)
GILD   69.22 (+3.31%)
Log in

NASDAQ:QTRX - Quanterix Stock Price, Forecast & News

$28.06
-0.34 (-1.20 %)
(As of 02/21/2020 02:59 PM ET)
Today's Range
$27.67
Now: $28.06
$28.60
50-Day Range
$21.63
MA: $25.67
$28.72
52-Week Range
$19.08
Now: $28.06
$36.15
Volume2,684 shs
Average Volume103,249 shs
Market Capitalization$785.96 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTRX
CUSIPN/A
Phone617-301-9400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.63 million
Book Value$1.85 per share

Profitability

Net Income$-31,540,000.00

Miscellaneous

Employees177
Market Cap$785.96 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.


Quanterix (NASDAQ:QTRX) Frequently Asked Questions

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

When is Quanterix's next earnings date?

Quanterix is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Quanterix.

What price target have analysts set for QTRX?

2 equities research analysts have issued 1-year target prices for Quanterix's stock. Their forecasts range from $35.00 to $35.00. On average, they expect Quanterix's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price. View Analyst Price Targets for Quanterix.

What is the consensus analysts' recommendation for Quanterix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix.

What are Wall Street analysts saying about Quanterix stock?

Here are some recent quotes from research analysts about Quanterix stock:
  • 1. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (1/8/2020)
  • 2. Canaccord Genuity analysts commented, "We come away feeling good about the momentum building, as QTRX is ~3% penetrated into the life sciences research market. QTRX is executing well above its 40%+ rev. growth target, and sits on new product launches. We reiterate our BUY, raise our PT to $38 from $35. One competitor just shut its doors. We were recently surprised to hear directly from privately-held Singulex CEO Guido Baechler (who employed 71 people and invested $225M+ into its business) that the company shuttered its business on June 28, 2019. With one less competitor, we expect QTRX to continue steamrolling ahead. QTRX is well positioned for elite growth. QTRX has grown its top line +70% in its trailing four quarters and is now rolling out new products, and feels good about Street’s $50.7M (+35%) estimate for 2019." (7/24/2019)

Has Quanterix been receiving favorable news coverage?

Media coverage about QTRX stock has been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Quanterix earned a news impact score of -4.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Quanterix.

Who are some of Quanterix's key competitors?

What other stocks do shareholders of Quanterix own?

Who are Quanterix's key executives?

Quanterix's management team includes the folowing people:
  • Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)
  • Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)
  • Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)
  • Mr. Amol Chaubal, Chief Financial Officer (Age 43)
  • Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 60)

When did Quanterix IPO?

(QTRX) raised $50 million in an IPO on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Who are Quanterix's major shareholders?

Quanterix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (3.17%), Royce & Associates LP (1.86%), State Street Corp (0.86%), Bank of New York Mellon Corp (0.74%), Kornitzer Capital Management Inc. KS (0.73%) and Geode Capital Management LLC (0.68%). Company insiders that own Quanterix stock include David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John M Connolly, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey and Martin D Madaus. View Institutional Ownership Trends for Quanterix.

Which institutional investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Barclays PLC, Credit Suisse AG, Bank of America Corp DE, Advisory Research Inc., AQR Capital Management LLC, Carnegie Capital Asset Management LLC and Geode Capital Management LLC. Company insiders that have sold Quanterix company stock in the last year include David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, Marijn E Dekkers, Mark T Roskey and Martin D Madaus. View Insider Buying and Selling for Quanterix.

Which institutional investors are buying Quanterix stock?

QTRX stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Kornitzer Capital Management Inc. KS, Bank of Montreal Can, State Street Corp, Platinum Investment Management Ltd., Renaissance Technologies LLC, Goldman Sachs Group Inc. and First Republic Investment Management Inc.. View Insider Buying and Selling for Quanterix.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $28.06.

How big of a company is Quanterix?

Quanterix has a market capitalization of $785.96 million and generates $37.63 million in revenue each year. The company earns $-31,540,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Quanterix employs 177 workers across the globe.View Additional Information About Quanterix.

What is Quanterix's official website?

The official website for Quanterix is http://www.quanterix.com/.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400.


MarketBeat Community Rating for Quanterix (NASDAQ QTRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  267 (Vote Underperform)
Total Votes:  491
MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: Percentage Decliners

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel